Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Lixisenatide requires daily injections, while newer GLP-1-targeting drugs like Ozempic ... and orally-active formulations are also coming through the pipeline. Given the huge unmet need for ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...

No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.